期刊
JOURNAL OF INTERNAL MEDICINE
卷 275, 期 5, 页码 444-455出版社
WILEY
DOI: 10.1111/joim.12225
关键词
antibody; envelope glycoprotein; human immunodeficiency virus; vaccine
资金
- European Union
- Swedish Medical Research Council
- UK Medical Research Council
- Bill & Melinda Gates Foundation
Despite the great advances made in controlling human immunodeficiency virus type 1 (HIV-1) infection with antiretroviral drug treatment, a safe and efficacious HIV vaccine has yet to be developed. Here, we discuss why clinical trials and vaccine development for HIV have so far been disappointing, with an emphasis on the lack of protective antibodies. We review approaches for developing appropriate HIV immunogens and the stimulation of long-lasting B-cell responses with antibody maturation. We conclude that candidate reagents in the pipeline for HIV vaccine development are unlikely to be particularly effective. Although the major funders of HIV vaccine research and development are placing increasing emphasis on clinical product development, a genuine breakthrough in preventing HIV infection through vaccines is more likely to come from novel immunogen research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据